US 2025/0101083 A1 · EPITOPE PEPTIDE AND ANTIBODY FOR TREATING HBV INFECTION AND RELATED DISEASES

Abstract

The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and/or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and/or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.

Claims32

Dependent claims

A nanobody or antigen-binding fragment thereof capable of specifically binding to HBsAg, wherein the nanobody or antigen-binding fragments thereof comprise:

CDR1 having the sequence as set forth in SEQ ID NO:
1 or a sequence having a substitution, deletion or addition of one or several amino acids (e.g., a substitution, deletion or addition of 1, 2 or 3 amino acids) as compared thereto;
CDR2 having the sequence as set forth in SEQ ID NO:
2 or a sequence having a substitution, deletion or addition of one or several amino acids (e.g., a substitution, deletion or addition of 1, 2 or 3 amino acids) as compared thereto;
and, CDR3 having the sequence as set forth in SEQ ID NO:
3 or a sequence having a substitution, deletion or addition of one or several amino acids (e.g., a substitution, deletion or addition of 1, 2 or 3 amino acids) as compared thereto;
preferably, the nanobody or antigen-binding fragment thereof comprises the sequence as set forth in SEQ ID NO:
8 or 13, or a sequence having a sequence identity of at least 80%, at least 85%, at least 90%, at least 91%, or at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% as compared thereto, or a sequence having a substitution, deletion or addition of one or several amino acids (e.g., a substitution, deletion or addition of 1, 2, 3, 4 or 5 amino acids) as compared thereto.

5 more elements

An isolated epitope peptide or variant thereof, wherein the epitope peptide or variant thereof comprises an epitope located within amino acid residues 157 to 174 of HBsAg protein, and the epitope comprises at least amino acid residues 163 to 165 of HBsAg protein;

the variant differs from the epitope peptide from which it is derived by only a substitution of 1, 2, 3, 4, or 5 amino acid residues, and retains the biological function of the epitope peptide from which it is derived;
and the epitope peptide consists of 5 to 80 consecutive amino acid residues of HBsAg protein;
for example, the epitope comprises at least amino acid residues 163 to 166 of HBsAg protein;
for example, the epitope comprises at least amino acid residues 163 to 165 and amino acid residues 158, 160 and 171 of HBsAg protein;
for example, the epitope comprises at least amino acid residues 163 to 166 and amino acid residues 158, 160 and 171 of HBsAg protein.

2 more elements

Dependencies are inferred from the claim text.

Epitope peptide and antibody for treating hbv infection and related diseases

Life of this patent

Epitope peptide and antibody for treating hbv infection and related diseases

Life of this patent

Abstract

Claims32